NYSE · CIK 0000874501
OSG AMBAC FINANCIAL GROUP INC
Insider trading from SEC Form 4. Last filing 6 d ago. Close $4.62 on Oct 9, 2026, +17% from the 52-week low and -54% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
OSGOct 9, 2026 · close 4.62
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AMBAC FINANCIAL GROUP INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Jeffrey Scott Stein director buy | $97k 15,000 shares | +43% | - | |
| 56Moderate | Claude LeBlanc Chief Executive Officer buy | $260k 40,000 shares | +7% | - | |
| 58Moderate | Michael D Price director buy | $500k 76,986 shares | +86% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 3, 2026 | David Trick Exec VP, CFO & Treasurer | MOption exercise Common Stock | +3,047 | - | - | 270,143 | 6 d ago |
| Oct 3, 2026 | Claude LeBlanc Chief Executive Officer | MOption exercise Common Stock | +15,229 | - | - | 1,080,463 | 6 d ago |
| Oct 3, 2026 | R Sharon Smith Exec VP & Group COO | MOption exercise Common Stock | +2,539 | - | - | 158,865 | 6 d ago |
| Oct 3, 2026 | R Sharon Smith Exec VP & Group COO | FTax withholding Common Stock | -2,539 | $4.60 | $12k | 156,326 | 6 d ago |
| Oct 3, 2026 | Claude LeBlanc Chief Executive Officer | FTax withholding Common Stock | -8,421 | $4.60 | $39k | 1,072,042 | 6 d ago |
| Oct 3, 2026 | David Trick Exec VP, CFO & Treasurer | FTax withholding Common Stock | -3,047 | $4.60 | $14k | 267,096 | 6 d ago |
| Oct 3, 2026 | R Sharon Smith Exec VP & Group COO | MOption exercise Restricted Stock Unitsderivative | -55,433 | $0.00 | $0 | 64,881 | 6 d ago |
| Oct 3, 2026 | David Trick Exec VP, CFO & Treasurer | MOption exercise Restricted Stock Unitsderivative | -66,519 | $0.00 | $0 | 58,459 | 6 d ago |
| Oct 3, 2026 | Claude LeBlanc Chief Executive Officer | MOption exercise Common Stock | +11,628 | - | - | 1,083,670 | 6 d ago |
| Oct 3, 2026 | David Trick Exec VP, CFO & Treasurer | MOption exercise Deferred Share Unitsderivative | +63,472 | $0.00 | $0 | 120,015 | 6 d ago |
| Oct 3, 2026 | R Sharon Smith Exec VP & Group COO | MOption exercise Deferred Share Unitsderivative | +52,894 | $0.00 | $0 | 138,240 | 6 d ago |
| Oct 3, 2026 | Claude LeBlanc Chief Executive Officer | FTax withholding Common Stock | -11,638 | $4.60 | $54k | 1,072,032 | 6 d ago |
| Oct 3, 2026 | Claude LeBlanc Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -15,229 | $0.00 | $0 | 465,603 | 6 d ago |
| Oct 3, 2026 | Claude LeBlanc Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -232,816 | $0.00 | $0 | 232,787 | 6 d ago |
| Oct 3, 2026 | Claude LeBlanc Chief Executive Officer | MOption exercise Deferred Share Unitsderivative | +221,188 | $0.00 | $0 | 418,731 | 6 d ago |
| Oct 1, 2026 | Ian David Haft director | AGrant or award Restricted Stock Unitsderivative | +8,224 | $0.00 | $0 | 30,815 | 7 d ago |
| Oct 1, 2026 | Jeffrey Scott Stein director | AGrant or award Restricted Stock Unitsderivative | +8,224 | $0.00 | $0 | 30,815 | 7 d ago |
| Oct 1, 2026 | Lisa G Iglesias director | AGrant or award Restricted Stock Unitsderivative | +8,224 | $0.00 | $0 | 30,815 | 7 d ago |
| Oct 1, 2026 | Michael D Price director | AGrant or award Restricted Stock Unitsderivative | +8,224 | $0.00 | $0 | 30,815 | 7 d ago |
| Oct 1, 2026 | Kristi Ann Matus director | AGrant or award Restricted Stock Unitsderivative | +8,224 | $0.00 | $0 | 30,815 | 7 d ago |
| Oct 1, 2026 | Joan M Lammtennant director | AGrant or award Restricted Stock Unitsderivative | +8,224 | $0.00 | $0 | 30,815 | 7 d ago |
| May 14, 2025 | Jeffrey Scott Stein director | POpen-market purchase Common Stock, par value $0.01 per share | +10,000 | $6.45 | $65k | 45,000 | May 15, 2025 |
| May 14, 2025 | Jeffrey Scott Stein director | POpen-market purchase Common Stock, par value $0.01 per share | +5,000 | $6.48 | $32k | 50,000 | May 15, 2025 |
| May 14, 2025 | Claude LeBlanc Chief Executive Officer | POpen-market purchase Common Stock | +40,000 | $6.50 | $260k | 578,291 | May 14, 2025 |
| May 14, 2025 | Michael D Price director | POpen-market purchase Common Stock, par value $0.01 per share | +76,923 | $6.49 | $499k | 166,235 | May 14, 2025 |
| May 14, 2025 | Michael D Price director | POpen-market purchase Common Stock, par value $0.01 per share | +63 | $6.54 | $412 | 166,298 | May 14, 2025 |
| Apr 1, 2025 | Lisa G Iglesias director | AGrant or award Restricted Stock Unitsderivative | +5,728 | $0.00 | $0 | 60,724 | Apr 3, 2025 |
| Apr 1, 2025 | Ian David Haft director | AGrant or award Restricted Stock Unitsderivative | +5,728 | $0.00 | $0 | 124,868 | Apr 2, 2025 |
| Apr 1, 2025 | Joan M Lammtennant director | AGrant or award Restricted Stock Unitsderivative | +5,728 | $0.00 | $0 | 99,937 | Apr 2, 2025 |
| Apr 1, 2025 | Kristi Ann Matus director | AGrant or award Restricted Stock Unitsderivative | +5,728 | $0.00 | $0 | 32,126 | Apr 2, 2025 |
| Apr 1, 2025 | Michael D Price director | AGrant or award Restricted Stock Unitsderivative | +5,728 | $0.00 | $0 | 32,126 | Apr 2, 2025 |
| Apr 1, 2025 | Jeffrey Scott Stein director | AGrant or award Restricted Stock Unitsderivative | +5,728 | $0.00 | $0 | 160,754 | Apr 2, 2025 |
| Mar 13, 2025 | David Barranco Senior Managing Director | MOption exercise Common Stock | +189 | $0.00 | $0 | 128,604 | Mar 14, 2025 |
| Mar 13, 2025 | Robert Bryan Eisman Sr. MD & CAO | MOption exercise Common Stock | +1,908 | $0.00 | $0 | 70,795 | Mar 14, 2025 |
| Mar 13, 2025 | Stephen Michael Ksenak Sr. MD & General Counsel | MOption exercise Common Stock | +4,726 | $0.00 | $0 | 123,302 | Mar 14, 2025 |
| Mar 13, 2025 | Claude LeBlanc Chief Executive Officer | MOption exercise Common Stock | +24,327 | $0.00 | $0 | 551,743 | Mar 14, 2025 |
| Mar 13, 2025 | Daniel McGinnis Sr. MD & COO | MOption exercise Common Stock | +94 | $0.00 | $0 | 18,550 | Mar 14, 2025 |
| Mar 13, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | MOption exercise Common Stock | +238 | $0.00 | $0 | 74,945 | Mar 14, 2025 |
| Mar 13, 2025 | David Trick Exec VP, CFO & Treasurer | MOption exercise Common Stock | +267 | $0.00 | $0 | 156,349 | Mar 14, 2025 |
| Mar 13, 2025 | David Barranco Senior Managing Director | FTax withholding Common Stock | -189 | $8.39 | $1,586 | 128,415 | Mar 14, 2025 |
| Mar 13, 2025 | Robert Bryan Eisman Sr. MD & CAO | FTax withholding Common Stock | -687 | $8.39 | $5,764 | 70,108 | Mar 14, 2025 |
| Mar 13, 2025 | Stephen Michael Ksenak Sr. MD & General Counsel | FTax withholding Common Stock | -1,703 | $8.39 | $14k | 121,599 | Mar 14, 2025 |
| Mar 13, 2025 | Claude LeBlanc Chief Executive Officer | FTax withholding Common Stock | -13,452 | $8.39 | $113k | 538,291 | Mar 14, 2025 |
| Mar 13, 2025 | Daniel McGinnis Sr. MD & COO | FTax withholding Common Stock | -94 | $8.39 | $789 | 18,456 | Mar 14, 2025 |
| Mar 13, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | FTax withholding Common Stock | -238 | $8.39 | $1,997 | 74,707 | Mar 14, 2025 |
| Mar 13, 2025 | David Trick Exec VP, CFO & Treasurer | FTax withholding Common Stock | -267 | $8.39 | $2,240 | 156,349 | Mar 14, 2025 |
| Mar 13, 2025 | David Barranco Senior Managing Director | MOption exercise Restricted Stock Unitsderivative | -5,167 | $0.00 | $0 | 16,117 | Mar 14, 2025 |
| Mar 13, 2025 | Robert Bryan Eisman Sr. MD & CAO | MOption exercise Restricted Stock Unitsderivative | -1,908 | $0.00 | $0 | 5,604 | Mar 14, 2025 |
| Mar 13, 2025 | Stephen Michael Ksenak Sr. MD & General Counsel | MOption exercise Restricted Stock Unitsderivative | -4,726 | $0.00 | $0 | 14,054 | Mar 14, 2025 |
| Mar 13, 2025 | Claude LeBlanc Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -24,327 | $0.00 | $0 | 71,456 | Mar 14, 2025 |
| Mar 13, 2025 | Daniel McGinnis Sr. MD & COO | MOption exercise Restricted Stock Unitsderivative | -2,584 | $0.00 | $0 | 8,058 | Mar 14, 2025 |
| Mar 13, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | MOption exercise Restricted Stock Unitsderivative | -4,961 | $0.00 | $0 | 15,698 | Mar 14, 2025 |
| Mar 13, 2025 | David Trick Exec VP, CFO & Treasurer | MOption exercise Restricted Stock Unitsderivative | -5,562 | $0.00 | $0 | 17,601 | Mar 14, 2025 |
| Mar 13, 2025 | David Barranco Senior Managing Director | MOption exercise Restricted Stock Unitsderivative | -189 | $0.00 | $0 | 15,928 | Mar 14, 2025 |
| Mar 13, 2025 | Daniel McGinnis Sr. MD & COO | MOption exercise Restricted Stock Unitsderivative | -94 | $0.00 | $0 | 7,964 | Mar 14, 2025 |
| Mar 13, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | MOption exercise Restricted Stock Unitsderivative | -238 | $0.00 | $0 | 15,460 | Mar 14, 2025 |
| Mar 11, 2025 | David Trick Exec VP, CFO & Treasurer | MOption exercise Restricted Stock Unitsderivative | -267 | $0.00 | $0 | 17,334 | Mar 14, 2025 |
| Mar 13, 2025 | David Barranco Senior Managing Director | MOption exercise Deferred Share Unitsderivative | +5,167 | $0.00 | $0 | 96,877 | Mar 14, 2025 |
| Mar 13, 2025 | Daniel McGinnis Sr. MD & COO | MOption exercise Deferred Share Unitsderivative | +2,584 | $0.00 | $0 | 29,832 | Mar 14, 2025 |
| Mar 13, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | MOption exercise Deferred Share Unitsderivative | +4,961 | $0.00 | $0 | 145,135 | Mar 14, 2025 |
| Mar 13, 2025 | David Trick Exec VP, CFO & Treasurer | MOption exercise Deferred Share Unitsderivative | +5,562 | $0.00 | $0 | 165,361 | Mar 14, 2025 |
| Mar 6, 2025 | David Trick Exec VP, CFO & Treasurer | MOption exercise Common Stock | +2,446 | $0.00 | $0 | 158,528 | Mar 10, 2025 |
| Mar 6, 2025 | Stephen Michael Ksenak Sr. MD & General Counsel | MOption exercise Common Stock | +1,967 | $0.00 | $0 | 118,576 | Mar 10, 2025 |
| Mar 6, 2025 | Robert Bryan Eisman Sr. MD & CAO | MOption exercise Common Stock | +1,271 | $0.00 | $0 | 68,887 | Mar 10, 2025 |
| Mar 6, 2025 | Daniel McGinnis Sr. MD & COO | MOption exercise Common Stock | +16,874 | $0.00 | $0 | 25,192 | Mar 10, 2025 |
| Mar 6, 2025 | David Barranco Senior Managing Director | AGrant or award Common Stock | +17,519 | $0.00 | $0 | 135,794 | Mar 10, 2025 |
| Mar 6, 2025 | Claude LeBlanc Chief Executive Officer | AGrant or award Common Stock | +10,809 | $0.00 | $0 | 538,225 | Mar 10, 2025 |
| Mar 6, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | MOption exercise Common Stock | +2,154 | $0.00 | $0 | 76,861 | Mar 10, 2025 |
| Mar 6, 2025 | David Trick Exec VP, CFO & Treasurer | FTax withholding Common Stock | -2,446 | $9.16 | $22k | 156,082 | Mar 10, 2025 |
| Mar 6, 2025 | Stephen Michael Ksenak Sr. MD & General Counsel | FTax withholding Common Stock | -1,967 | $9.16 | $18k | 118,576 | Mar 10, 2025 |
| Mar 6, 2025 | Robert Bryan Eisman Sr. MD & CAO | FTax withholding Common Stock | -1,271 | $9.16 | $12k | 68,887 | Mar 10, 2025 |
| Mar 6, 2025 | Daniel McGinnis Sr. MD & COO | FTax withholding Common Stock | -6,736 | $9.16 | $62k | 18,456 | Mar 10, 2025 |
| Mar 6, 2025 | David Barranco Senior Managing Director | FTax withholding Common Stock | -7,379 | $9.16 | $68k | 128,415 | Mar 10, 2025 |
| Mar 6, 2025 | Claude LeBlanc Chief Executive Officer | FTax withholding Common Stock | -10,809 | $9.16 | $99k | 527,416 | Mar 10, 2025 |
| Mar 6, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | FTax withholding Common Stock | -2,154 | $9.16 | $20k | 74,707 | Mar 10, 2025 |
| Mar 6, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | AGrant or award Deferred Share Unitsderivative | +59,408 | $0.00 | $0 | 140,174 | Mar 10, 2025 |
| Mar 6, 2025 | David Trick Exec VP, CFO & Treasurer | AGrant or award Deferred Share Unitsderivative | +66,577 | $0.00 | $0 | 159,799 | Mar 10, 2025 |
| Mar 6, 2025 | Stephen Michael Ksenak Sr. MD & General Counsel | AGrant or award Deferred Share Unitsderivative | +53,999 | $0.00 | $0 | 129,146 | Mar 10, 2025 |
| Mar 6, 2025 | Robert Bryan Eisman Sr. MD & CAO | AGrant or award Deferred Share Unitsderivative | +21,117 | $0.00 | $0 | 50,852 | Mar 10, 2025 |
| Mar 6, 2025 | Daniel McGinnis Sr. MD & COO | AGrant or award Deferred Share Unitsderivative | +14,838 | $0.00 | $0 | 27,248 | Mar 10, 2025 |
| Mar 6, 2025 | David Barranco Senior Managing Director | AGrant or award Deferred Share Unitsderivative | +45,907 | $0.00 | $0 | 91,710 | Mar 10, 2025 |
| Mar 6, 2025 | Claude LeBlanc Chief Executive Officer | AGrant or award Deferred Share Unitsderivative | +274,612 | $0.00 | $0 | 661,355 | Mar 10, 2025 |
| Feb 28, 2025 | David Trick Exec VP, CFO & Treasurer | MOption exercise Common Stock | +663 | - | - | 156,745 | Mar 4, 2025 |
| Feb 28, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | MOption exercise Common Stock | +641 | - | - | 75,348 | Mar 4, 2025 |
| Feb 28, 2025 | Claude LeBlanc Chief Executive Officer | MOption exercise Common Stock | +1,152 | - | - | 528,568 | Mar 4, 2025 |
| Feb 28, 2025 | Robert Bryan Eisman Sr. MD & CAO | MOption exercise Common Stock | +233 | - | - | 67,849 | Mar 4, 2025 |
| Feb 28, 2025 | David Barranco Senior Managing Director | MOption exercise Common Stock | +5,725 | - | - | 117,530 | Mar 4, 2025 |
| Feb 28, 2025 | Daniel McGinnis Sr. MD & COO | MOption exercise Common Stock | +330 | - | - | 8,648 | Mar 4, 2025 |
| Feb 28, 2025 | Stephen Michael Ksenak Sr. MD & General Counsel | MOption exercise Common Stock | +582 | - | - | 117,191 | Mar 4, 2025 |
| Feb 28, 2025 | Claude LeBlanc Chief Executive Officer | FTax withholding Common Stock | -1,152 | $9.71 | $11k | 527,416 | Mar 4, 2025 |
| Feb 28, 2025 | David Barranco Senior Managing Director | FTax withholding Common Stock | -2,370 | $9.71 | $23k | 115,160 | Mar 4, 2025 |
| Feb 28, 2025 | David Trick Exec VP, CFO & Treasurer | FTax withholding Common Stock | -663 | $9.71 | $6,438 | 156,082 | Mar 4, 2025 |
| Feb 28, 2025 | R Sharon Smith Exec VP & Chief Strategy Offr | FTax withholding Common Stock | -641 | $9.71 | $6,224 | 74,707 | Mar 4, 2025 |
| Feb 28, 2025 | Daniel McGinnis Sr. MD & COO | FTax withholding Common Stock | -330 | $9.71 | $3,204 | 8,318 | Mar 4, 2025 |
| Feb 28, 2025 | Stephen Michael Ksenak Sr. MD & General Counsel | FTax withholding Common Stock | -582 | $9.71 | $5,651 | 116,609 | Mar 4, 2025 |
| Feb 28, 2025 | Robert Bryan Eisman Sr. MD & CAO | FTax withholding Common Stock | -233 | $9.71 | $2,262 | 67,616 | Mar 4, 2025 |
| Mar 3, 2025 | David Barranco Senior Managing Director | MOption exercise Common Stock | +5,214 | - | - | 120,374 | Mar 4, 2025 |
| Mar 3, 2025 | Robert Bryan Eisman Sr. MD & CAO | MOption exercise Common Stock | +212 | - | - | 67,828 | Mar 4, 2025 |
| Mar 3, 2025 | Stephen Michael Ksenak Sr. MD & General Counsel | MOption exercise Common Stock | +400 | - | - | 117,009 | Mar 4, 2025 |
| Mar 3, 2025 | Claude LeBlanc Chief Executive Officer | MOption exercise Common Stock | +888 | - | - | 528,304 | Mar 4, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- David BarrancoSenior Managing Director
- Robert Bryan EismanSr. MD & CAO
- Ian David Haftdirector
- Lisa G Iglesiasofficer, director
- Stephen Michael KsenakSr. MD & General Counsel
- Joan M Lammtennantdirector
- Claude LeBlancChief Executive Officer
- Kristi Ann Matusdirector
- Daniel McGinnisSr. MD & COO
- Michael D Pricedirector
- R Sharon SmithExec VP & Group COO
- Jeffrey Scott Steindirector
- David TrickExec VP, CFO & Treasurer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.